Durable activity of NVL-655 and zidesamtinib in heavily pre-treated patient populations supports ongoing Phase 2 investigation in earlier lines of treatment "Our development strategy has been anchored ...
Harper Hubbeling, MD; Noura Choudhury, MD; Jessica Flynn, BS; Zhigang Zhang, PhD; Christina Falcon, MPH; Valerie W. Rusch, MD; Bernard J. Park, MD; Etay Ziv, MD, PhD ...
Zidesamtinib is a novel brain-penetrant ROS1-selective inhibitor created with the aim to overcome limitations observed with currently available ROS1 inhibitors. Zidesamtinib is designed to remain ...
Rapid enrollment in Phase 2 portions of the ARROS-1 and ALKOVE-1 clinical trials; Pivotal data from both ROS1 and ALK programs now anticipated in 2025 Initiation of ALKAZAR Phase 3 randomized, ...
Cost-Effectiveness Analysis of Denosumab in the Prevention of Skeletal-Related Events Among Patients With Breast Cancer With Bone Metastasis in India The Markov model consisted of three health states: ...
The signature program, a series of tissue-agnostic, mutation-specific signal finding trials. Background: Crizotinib (czb) is registered only for the treatment of patients (pts) with ALK+ lung cancer.
SUZHOU, China, and ROCKVILLE, MD, June 7, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B ...
This summer’s phase III news from Qilu Pharmaceutical Co. Ltd. with iruplinalkib – an oral inhibitor of ALK and ROS1 tyrosine kinase – reinforced an ongoing interest in the pair of oncology targets, ...
SUZHOU, China, and ROCKVILLE, MD, June 7, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback